{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:50:56Z","timestamp":1788493856290,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) is a neurodegenerative disorder leading to dementia. Aggregation of the amyloid-\u03b2 peptide (A\u03b2) plays an important role in the disease, with A\u03b2 oligomers representing the most toxic species. Previously, we have developed the A\u03b2 oligomer eliminating therapeutic compound RD2 consisting solely of D-enantiomeric amino acid residues. RD2 has been described to have an oral bioavailability of more than 75% and to improve cognition in transgenic Alzheimer\u2019s disease mouse models after oral administration. In the present study, we further examined the stability of RD2 in simulated gastrointestinal fluids, blood plasma and liver microsomes. In addition, we have examined whether RD2 is a substrate for the human D-amino acid oxidase (hDAAO). Furthermore, metabolite profiles of RD2 incubated in human, rodent and non-rodent liver microsomes were compared across species to search for human-specific metabolites that might possibly constitute a threat when applying the compound in humans. RD2 was remarkably resistant against metabolization in all investigated media and not converted by hDAAO. Moreover, RD2 did not influence the activity of any of the tested enzymes. In conclusion, the high stability and the absence of relevant human-specific metabolites support RD2 to be safe for oral administration in humans.<\/jats:p>","DOI":"10.1038\/s41598-019-41993-6","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:02:56Z","timestamp":1554458576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-\u03b2 oligomers"],"prefix":"10.1038","volume":"9","author":[{"given":"Anne","family":"Elfgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hupert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bochinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0530-7469","authenticated-orcid":false,"given":"Markus","family":"Tusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estibaliz","family":"Gonz\u00e1lez de San Rom\u00e1n Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Gering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-2561","authenticated-orcid":false,"given":"Silvia","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-7243","authenticated-orcid":false,"given":"Loredano","family":"Pollegioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0335-2242","authenticated-orcid":false,"given":"Pitter F.","family":"Huesgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7807-6273","authenticated-orcid":false,"given":"Rudolf","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Santiago-Sch\u00fcbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Kutzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-7366","authenticated-orcid":false,"given":"Dieter","family":"Willbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"41993_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","volume":"88","author":"C Reitz","year":"2014","unstructured":"Reitz, C. & Mayeux, R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochemical pharmacology 88, 640\u2013651, https:\/\/doi.org\/10.1016\/j.bcp.2013.12.024 (2014).","journal-title":"Biochemical pharmacology"},{"key":"41993_CR2","doi-asserted-by":"publisher","unstructured":"Terry-Lorenzo, R. T. et al. Novel human D-amino acid oxidase inhibitors stabilize an active-site lid-open conformation. Biosci Rep 34, https:\/\/doi.org\/10.1042\/BSR20140071 (2014).","DOI":"10.1042\/BSR20140071"},{"key":"41993_CR3","first-page":"217","volume":"29","author":"P Taavitsainen","year":"2001","unstructured":"Taavitsainen, P., Juvonen, R. & Pelkonen, O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 29, 217\u2013222 (2001).","journal-title":"Drug Metab Dispos"},{"key":"41993_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO molecular medicine 8, 595\u2013608, https:\/\/doi.org\/10.15252\/emmm.201606210 (2016).","journal-title":"EMBO molecular medicine"},{"key":"41993_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nature reviews. Drug discovery 10, 698\u2013712, https:\/\/doi.org\/10.1038\/nrd3505 (2011).","journal-title":"Nature reviews. Drug discovery"},{"key":"41993_CR6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2174\/138161212799277752","volume":"18","author":"A Funke","year":"2012","unstructured":"Funke, A. & Willbold, D. Peptides for Therapy and Diagnosis of Alzheimer\u2019s Disease. Curr Pharm Des 18, 755\u2013767 (2012).","journal-title":"Curr Pharm Des"},{"key":"41993_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2174\/138955712800493942","volume":"12","author":"N Sun","year":"2012","unstructured":"Sun, N., Funke, S. A. & Willbold, D. A survey of peptides with effective therapeutic potential in Alzheimer\u2019s disease rodent models or in human clinical studies. Mini-Rev Med Chem 12, 388\u2013398 (2012).","journal-title":"Mini-Rev Med Chem"},{"key":"41993_CR8","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 95, 6448\u20136453 (1998).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"41993_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh, D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535\u2013539 (2002).","journal-title":"Nature"},{"key":"41993_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/NEN.0b013e318217a118","volume":"70","author":"B DaRocha-Souto","year":"2011","unstructured":"DaRocha-Souto, B. et al. Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein\/tau transgenic mice. Journal of neuropathology and experimental neurology 70, 360\u2013376, https:\/\/doi.org\/10.1097\/NEN.0b013e318217a118 (2011).","journal-title":"Journal of neuropathology and experimental neurology"},{"key":"41993_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer\u2019s disease: an emperor in need of clothes. Nature neuroscience 15, 349\u2013357, https:\/\/doi.org\/10.1038\/nn.3028 (2012).","journal-title":"Nature neuroscience"},{"key":"41993_CR12","doi-asserted-by":"publisher","first-page":"11506","DOI":"10.1002\/anie.201706279","volume":"56","author":"S Dutta","year":"2017","unstructured":"Dutta, S. et al. Suppression of Oligomer Formation and Formation of Non-Toxic Fibrils upon Addition of Mirror-Image Abeta42 to the Natural l-Enantiomer. Angew Chem Int Ed Engl 56, 11506\u201311510, https:\/\/doi.org\/10.1002\/anie.201706279 (2017).","journal-title":"Angew Chem Int Ed Engl"},{"key":"41993_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16565-1","volume":"7","author":"T van Groen","year":"2017","unstructured":"van Groen, T. et al. The A\u03b2 oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci Rep 7, 16275, https:\/\/doi.org\/10.1038\/s41598-017-16565-1 (2017).","journal-title":"Sci Rep"},{"key":"41993_CR14","doi-asserted-by":"publisher","unstructured":"Kutzsche, J. et al. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer\u2019s Disease. Molecules 22, https:\/\/doi.org\/10.3390\/molecules22101693 (2017).","DOI":"10.3390\/molecules22101693"},{"key":"41993_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11095-015-1791-2","volume":"33","author":"LH Leithold","year":"2016","unstructured":"Leithold, L. H. et al. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic beta-Amyloid Oligomers. Pharmaceutical research 33, 328\u2013336, https:\/\/doi.org\/10.1007\/s11095-015-1791-2 (2016).","journal-title":"Pharmaceutical research"},{"key":"41993_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1006\/bbrc.1996.1413","volume":"226","author":"C Soto","year":"1996","unstructured":"Soto, C., Kindy, M. S., Baumann, M. & Frangione, B. Inhibition of Alzheimer\u2019s amyloidosis by peptides that prevent beta-sheet conformation. Biochemical and biophysical research communications 226, 672\u2013680 (1996).","journal-title":"Biochemical and biophysical research communications"},{"key":"41993_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/(SICI)1097-4695(19990605)39:3<371::AID-NEU4>3.0.CO;2-E","volume":"39","author":"JF Poduslo","year":"1998","unstructured":"Poduslo, J. F., Curran, G. L., Kumar, A., Frangione, B. & Soto, C. Beta-sheet breaker peptide inhibitor of Alzheimer\u2019s amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 39, 371\u2013382 (1998).","journal-title":"J Neurobiol"},{"key":"41993_CR18","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1021\/bi982824n","volume":"38","author":"MA Findeis","year":"1999","unstructured":"Findeis, M. A. et al. Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochem 38, 6791\u20136800, https:\/\/doi.org\/10.1021\/bi982824n (1999).","journal-title":"Biochem"},{"key":"41993_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1515\/BC.2003.044","volume":"384","author":"A Elmquist","year":"2003","unstructured":"Elmquist, A. & Langel, U. In vitro Uptake and Stability Study of pVEC and Its All-D Analog. Biol Chem 384, 387\u2013393 (2003).","journal-title":"Biol Chem"},{"key":"41993_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/ddr.430350105","volume":"35","author":"SM Miller","year":"1995","unstructured":"Miller, S. M. et al. Comparison of the Proteolytic Susceptibilities of Homologous L-Amino Acid, D-Amino Acid, and N-Substituted Clycine Peptide and Peptoid Oligomers. Drug Dev Res 35, 20\u201332 (1995).","journal-title":"Drug Dev Res"},{"key":"41993_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1073\/pnas.0407677102","volume":"102","author":"R Tugyi","year":"2005","unstructured":"Tugyi, R. et al. Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proceedings of the National Academy of Sciences of the United States of America 102, 413\u2013418, https:\/\/doi.org\/10.1073\/pnas.0407677102 (2005).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"41993_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","volume":"30","author":"M Werle","year":"2006","unstructured":"Werle, M. & Bernkop-Schnurch, A. Strategies to improve plasma half life time of peptide and protein drugs. Amino acids 30, 351\u2013367, https:\/\/doi.org\/10.1007\/s00726-005-0289-3 (2006).","journal-title":"Amino acids"},{"key":"41993_CR23","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1021\/mp500809f","volume":"12","author":"J Wang","year":"2015","unstructured":"Wang, J., Yadav, V., Smart, A. L., Tajiri, S. & Basit, A. W. Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Molecular pharmaceutics 12, 966\u2013973, https:\/\/doi.org\/10.1021\/mp500809f (2015).","journal-title":"Molecular pharmaceutics"},{"key":"41993_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejps.2017.07.015","volume":"107","author":"A Elfgen","year":"2017","unstructured":"Elfgen, A., Santiago-Schubel, B., Gremer, L., Kutzsche, J. & Willbold, D. Surprisingly high stability of the Abeta oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 107, 203\u2013207, https:\/\/doi.org\/10.1016\/j.ejps.2017.07.015 (2017).","journal-title":"European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences"},{"key":"41993_CR25","doi-asserted-by":"crossref","first-page":"26941","DOI":"10.1016\/S0021-9258(19)74201-X","volume":"268","author":"A D\u2019Aniello","year":"1993","unstructured":"D\u2019Aniello, A. et al. Biological Role of D-Amino Acid Oxidase and D-Aspartate Oxidase. Effects of D-amino acids. J Biol Chem 268, 26941\u201326949 (1993).","journal-title":"J Biol Chem"},{"key":"41993_CR26","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1016\/j.jchromb.2011.06.028","volume":"879","author":"H Ohide","year":"2011","unstructured":"Ohide, H., Miyoshi, Y., Maruyama, R., Hamase, K. & Konno, R. D-Amino acid metabolism in mammals: biosynthesis, degradation and analytical aspects of the metabolic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 879, 3162\u20133168, https:\/\/doi.org\/10.1016\/j.jchromb.2011.06.028 (2011).","journal-title":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"key":"41993_CR27","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00726-012-1384-x","volume":"43","author":"M Yamanaka","year":"2012","unstructured":"Yamanaka, M., Miyoshi, Y., Ohide, H., Hamase, K. & Konno, R. D-Amino acids in the brain and mutant rodents lacking D-amino-acid oxidase activity. Amino acids 43, 1811\u20131821, https:\/\/doi.org\/10.1007\/s00726-012-1384-x (2012).","journal-title":"Amino acids"},{"key":"41993_CR28","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00726-012-1345-4","volume":"43","author":"S Sacchi","year":"2012","unstructured":"Sacchi, S., Caldinelli, L., Cappelletti, P., Pollegioni, L. & Molla, G. Structure-function relationships in human D-amino acid oxidase. Amino acids 43, 1833\u20131850, https:\/\/doi.org\/10.1007\/s00726-012-1345-4 (2012).","journal-title":"Amino acids"},{"key":"41993_CR29","doi-asserted-by":"crossref","unstructured":"Iverson, S. L. Metabolite Safety in Drug Development. (John Wiley & Sons, 2016).","DOI":"10.1002\/9781118949689"},{"key":"41993_CR30","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.febslet.2006.03.045","volume":"580","author":"G Molla","year":"2006","unstructured":"Molla, G. et al. Characterization of human D-amino acid oxidase. FEBS letters 580, 2358\u20132364, https:\/\/doi.org\/10.1016\/j.febslet.2006.03.045 (2006).","journal-title":"FEBS letters"},{"key":"41993_CR31","first-page":"321","volume":"277","author":"M Bourrie","year":"1996","unstructured":"Bourrie, M., Meunier, V., Berger, Y. & Fabre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. The Journal of pharmacology and experimental therapeutics 277, 321\u2013332 (1996).","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"41993_CR32","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2174\/138920007782798207","volume":"8","author":"L Jia","year":"2007","unstructured":"Jia, L. & Liu, X. The Conduct of Drug Metabolism Studies Considered Good Practice (II). In Vitro Experiments. Curr Drug Metab. 8, 822\u2013829 (2007).","journal-title":"Curr Drug Metab."},{"key":"41993_CR33","doi-asserted-by":"crossref","unstructured":"Wu, W. N. & McKown, L. A. In Optimization in Drug Discovery. In Vitro Methods. Methods in Pharmacology and Toxicology (eds Yan, Z. & Caldwell, G. W.) 163-184 (Humana Press, 2004).","DOI":"10.1385\/1-59259-800-5:163"},{"key":"41993_CR34","unstructured":"U.S. Food and Drug Administration. (ed. U.S. Department of Health and Human Services) (2008)."},{"key":"41993_CR35","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1074\/jbc.M310752200","volume":"279","author":"B Metz","year":"2004","unstructured":"Metz, B. et al. Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J Biol Chem 279, 6235\u20136243, https:\/\/doi.org\/10.1074\/jbc.M310752200 (2004).","journal-title":"J Biol Chem"},{"key":"41993_CR36","doi-asserted-by":"crossref","unstructured":"Keil, B. Specificity of proteolysis. (Springer-Verlag, 1992).","DOI":"10.1007\/978-3-642-48380-6"},{"key":"41993_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1021\/ar50027a001","volume":"3","author":"WN Lipscomb","year":"1970","unstructured":"Lipscomb, W. N. Structure and Mechanism in the Enzymatic Activity of Carboxypeptidase A and Relations to Chemical Sequence. Acc. Chem. Res. 3, 81\u201389 (1970).","journal-title":"Acc. Chem. Res."},{"key":"41993_CR38","doi-asserted-by":"crossref","unstructured":"Christianson, D. W. & Lipscomb, W. N. Carboxypeptidase A. Acc. Chem. Res. 22, 62\u201369 (1989).","DOI":"10.1021\/ar00158a003"},{"key":"41993_CR39","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1021\/ja01595a077","volume":"78","author":"JE Folk","year":"1956","unstructured":"Folk, J. E. A New Pancreatic Carboxypeptidase. J. Am. Chem. Soc. 78, 3541\u20133542 (1956).","journal-title":"J. Am. Chem. Soc."},{"key":"41993_CR40","first-page":"2460","volume":"35","author":"AY Lu","year":"1976","unstructured":"Lu, A. Y. Liver microsomal drug-metabolizing enzyme system: functional components and their properties. Fed Proc 35, 2460\u20132463 (1976).","journal-title":"Fed Proc"},{"key":"41993_CR41","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/1521-3765(20010216)7:4<910::AID-CHEM910>3.0.CO;2-U","volume":"7","author":"AJ Heck","year":"2001","unstructured":"Heck, A. J., Bonnici, P. J., Breukink, E., Morris, D. & Wills, M. Modification and inhibition of vancomycin group antibiotics by formaldehyde and acetaldehyde. Chemistry 7, 910\u2013916 (2001).","journal-title":"Chemistry"},{"key":"41993_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/rcm.1290030912","volume":"3","author":"WR Mathews","year":"1989","unstructured":"Mathews, W. R., Runge, T. A., Haroldsen, P. E. & Gaskell, S. J. Characterization of impurities in a synthetic renin substrate peptide by fast-atom bombardment mass spectrometry and hybrid tandem mass spectrometry. Rapid Commun Mass Spectrom 3, 314\u2013319, https:\/\/doi.org\/10.1002\/rcm.1290030912 (1989).","journal-title":"Rapid Commun Mass Spectrom"},{"key":"41993_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0378-5173(91)90349-S","volume":"76","author":"GJ Rasmussen","year":"1991","unstructured":"Rasmussen, G. J. & Bundgaard, H. Prodrugs of peptides. 15. 4-Imidazolidinone prodrug derivatives of enkephalins to prevent aminopeptidase-catalyzed metabolism in plasma and absorptive mucosae. Int. J. Pharm. 76, 113\u2013122 (1991).","journal-title":"Int. J. Pharm."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41993-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41993-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41993-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:31:49Z","timestamp":1671265909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41993-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41993"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41993-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"5 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.W. is co-inventor of patents covering the composition of matter of RD2, which was used in the present study. D.W. is also co-founder and co-owner of the company \u201cPriavoid GmbH\u201d, which is developing RD2 further for clinical use. This did not have influence on any data evaluation or its interpretation. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5715"}}